Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Abstract

The bcr–abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease. A compound, designed to inhibit the Abl protein tyrosine kinase, was evaluated for its effects on cells containing the Bcr–Abl fusion protein. Cellular proliferation and tumor formation by Bcr–Abl–expressing cells were specifically inhibited by this compound. In colony–forming assays of peripheral blood or bone marrow from patients with CML, there was a 92–98% decrease in the number of bcr–abl colonies formed but no inhibition of normal colony formation. This compound may be useful in the treatment of bcr–abl–positive leukemias.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kantarjian, H.M., Deisseroth, A.B., Kurzrock, R., Estrov, Z., & Talpaz, M., Chronic myelogenous leukemia: A concise update. Blood 82, 691–703 (1993).

    CAS  PubMed  Google Scholar 

  2. Allan, N.C., Shepard, P.C.A. & Richards, R.M. Interferon alpha prolongs survival for patients with CML in chronic phase: Preliminary results of the UK MRC randomized multicenter trial. Blood 84, 382a (1994).

    Google Scholar 

  3. The Italian Cooperaticellve Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N. Engl. J. Med. 330, 820–825 (1994).

  4. Ozer, H., et al. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood. 82, 2975–2984 (1993).

    CAS  PubMed  Google Scholar 

  5. O'Brien, S.G. & Goldman, J.M. Autografting in chronic myeloid leukaemia. Blood Rev. 8, 63–69 (1994).

    Article  CAS  Google Scholar 

  6. McGlave, P.B., et al. Autologous transplants for chronic myelogenous leukaemia: Results from eight transplant groups. Lancet 343, 1486–1488 (1994).

    Article  CAS  Google Scholar 

  7. O'Brien, S.G. & Goldman, J.M. Current approaches to hematopoietic stem-Cell purging in chronic myeloid leukemia. J. Clin. Oncol. 13, 541–546 (1995).

    Article  CAS  Google Scholar 

  8. Nowell, P.C. & Hungerford, D.A. A minute chromosome in human chronic granulocytic leukemia. Science 132, 1497–1501 (1960).

    Google Scholar 

  9. Rowley, J.D. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine, fluorescence and Giemsa staining. Nature. 243, 290–293 (1973).

    Article  CAS  Google Scholar 

  10. Heisterkamp, N., et al. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukemia. Nature. 306, 239–242 (1983).

    Article  CAS  Google Scholar 

  11. Bartram, C.R. et al. Translocation of c-abl correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukemia. Nature. 306, 277–280 (1983).

    Article  CAS  Google Scholar 

  12. Shtivelman, E., Lifshitz, B., Gale, R.P. & Canaani, E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 315, 550–554 (1985).

    Article  CAS  Google Scholar 

  13. Clark, S.S., et al. Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science. 239, 775–777 (1988).

    Article  CAS  Google Scholar 

  14. Scott, M.L., Van Etten, R., Daley, G.Q. & Baltimore, D. v-abl causes hematopoietic disease distinct from that caused by bcr-abl. Proc. Natl. Acad. Sci. USA. 88, 6506–6510 (1991).

    Article  CAS  Google Scholar 

  15. Kelliher, M.A., McLaughlin, J., Witte, O.N. & Rosenberg, N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl. Acad. Sci. USA. 87, 6649–6653 (1990).

    Article  CAS  Google Scholar 

  16. Daley, G.Q., Van Etten, R.A. & Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 247, 824–830 (1990).

    Article  CAS  Google Scholar 

  17. Oda, T., Tamura, S., Matsuguchi, T., Griffin, J.D. & Druker, B.J. The SH2 domain of Abl is not required for factor independent growth induced by Bcr-Abl in a murine myeloid Cell line. Leukemia. 9, 295–301 (1995).

    CAS  PubMed  Google Scholar 

  18. Lugo, T.G., Pendergast, A.M., Muller, A.J. & Witte, O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 247, 1079–1082 (1990).

    Article  CAS  Google Scholar 

  19. Yaish, P., Gazit, A., Gilon, C. & Levitzki, A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 242, 933–935 (1988).

    Article  CAS  Google Scholar 

  20. Levitzki, A. & Gazit, A. Tyrosine kinase inhibition: An approach to drug development. Science. 267, 1782–1788 (1995).

    Article  CAS  Google Scholar 

  21. Kaur, G., et al. Tyrphostin induced growth inhibition: Correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia. Anti-Cancer Drugs. 5, 213–222 (1994).

    Article  CAS  Google Scholar 

  22. Anafi, M., Gazit, A., Zehavi, A., Ben-Neriah, Y. & Levitzki, A. Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood. 82, 3524–3529 (1993).

    CAS  PubMed  Google Scholar 

  23. Furet, P., et al. Modeling study of protein kinase inhibitors – binding mode of staurosporine and origin of the selectivity of CGP 52411. J Comput. Aided Mol. Des. 9, 465–472 (1995).

    Article  CAS  Google Scholar 

  24. Laneuville, P., Heisterkamp, N. & Groffen, J. Expression of the chronic myelogenous leukemia-associated p210bcr/abl oncoprotein in a murine IL-3 dependent myeloid Cell line. Oncogene 6, 275–282 (1991).

    CAS  PubMed  Google Scholar 

  25. Matulonis, U., Salgia, R., Okuda, K., Druker, B. & Griffin, J.D. IL-3 and p210BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid Cell line. Exp. Hematol. 21, 1460–1466 (1993).

    CAS  PubMed  Google Scholar 

  26. Daley, G.Q. & Baltimore, D. Transformation of an interleukin 3-dependent hematopoietic Cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc. Natl. Acad. Sci. USA. 85, 9312–9316 (1988).

    Article  CAS  Google Scholar 

  27. Honma, Y., Okabe, K.J., Hozumi, M., Uehara, Y. & Mizuno, S. Induction of ery-throid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity. Cancer Res. 49, 331–4 (1989).

    CAS  PubMed  Google Scholar 

  28. Schwartzberg, P.L., et al. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T Cell populations. Cell. 65, 1165–1175 (1991).

    Article  CAS  Google Scholar 

  29. Sawyers, C.L., McLaughlin, J., Goga, A., Havlik, M. & Witte, O. The nuclear tyrosine kinase c-Abl negatively regulates Cell growth. Cell. 77, 121–131 (1994).

    Article  CAS  Google Scholar 

  30. Silvennoinen, O., et al. Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. Proc. Natl. Acad. Sci. USA. 90, 8429–8433 (1993).

    Article  CAS  Google Scholar 

  31. Caracciolo, D., et al. Lineage-specific requirement of c-abl function in normal hematopoiesis. Science. 245, 1107–1110 (1989).

    Article  CAS  Google Scholar 

  32. Martiat, P., et al. Retrovirally transduced antisense sequences stably suppress p210BCR-ABL expression and inhibit the proliferation of BCR/ABL-containing Cell lines. Blood. 81, 502–509 (1993).

    CAS  PubMed  Google Scholar 

  33. Oda, T., et al. CRKL is the major tyrosine phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J. Biol. Chem. 269, 22925–22928 (1994).

    CAS  PubMed  Google Scholar 

  34. Evans, C.A., Owen-Lynch, P.J., Whetton, A.D. & Dive, C. Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic Cells. Cancer Res. 53, 1735–1738 (1993).

    CAS  PubMed  Google Scholar 

  35. Bedi, A., Zehnbauer, B.A., Barber, J.P., Sharkis, S.J. & Jones, R.J. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood. 83, 2038–2044 (1994).

    CAS  PubMed  Google Scholar 

  36. Heldin, C.H. & Westermark, B. Platelet-derived growth factor: Mechanism of action and possible in vivo function. Cell Regul. 1, 555–566 (1990).

    Article  CAS  Google Scholar 

  37. Kanakura, Y., et al. Signal transduction of the human granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors involves a common set of cytoplasmic proteins. Blood. 76, 706–715 (1990).

    CAS  PubMed  Google Scholar 

  38. Greenberger, J.S., Sakakeeny, M.A., Humphries, R.K., Eaves, C.J., & Eckner, R.J. Demonstration of permanent factor-dependent multipotential (erythroid/neu-trophil/basophil) hematopoietic progenitor cell lines. Proc. Natl. Acad. Sci. USA. 80, 2391–2395 (1983).

    Article  Google Scholar 

  39. Avanzi, G.C., et al. Selective growth response to IL-3 of a human leukaemic Cell line with megakaryoblastic features. Br. J. Haematol. 69, 359–366 (1988).

    Article  CAS  Google Scholar 

  40. Matsuguchi, T., et al. SHC phosphorylation in myeloid cells is regulated by GM-CSF, IL-3, and steel factor and is constitutively increased by p210BCR-ABL. J. Biol. Chem. 269, 5016–5021 (1994).

    CAS  PubMed  Google Scholar 

  41. Erwin, J.L. & Anderson, S.M. Analysis of phosphotyrosine-containing proteins present in v-src-infected myeloid progenitor cells. Oncogene 7, 1101–1107 (1992).

    CAS  PubMed  Google Scholar 

  42. Mossman, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55–63 (1983).

    Article  Google Scholar 

  43. Orkin, S.H., Harosi, F.I. & Leder, P. Differentiation in erythroleukemia cells and their somatic hybrids. Proc. Natl. Acad. Sci. USA. 72, 98–102 (1975).

    Article  CAS  Google Scholar 

  44. Buchdunger, E., et al. 4,5-Dianilinophthalimide: A protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. Proc. Natl. Acad. Sci. USA. 91, 2334–2338 (1994).

    Article  CAS  Google Scholar 

  45. Buchdunger, E., et al. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. USA 92, 2558–2562 (1995).

    Article  CAS  Google Scholar 

  46. Arion, D., Meijer, L., Brizuela, L. & Beach, D. cdc2 is a component of the M phase-specific histone HI kinase: Evidence for identity with MPF. Cell. 55, 371–378 (1988).

    Article  CAS  Google Scholar 

  47. Pendergast, A.M., et al. Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor. Proc. Natl. Acad. Sci. USA. 88, 5927–5931 (1991).

    Article  CAS  Google Scholar 

  48. Kharbanda, S., et al. Activation of the c-abl tyrosine kinase in stress response to DNA-damaging agents. Nature. 376, 785–788 (1995).

    Article  CAS  Google Scholar 

  49. Evans, B.D., Smith, I.E., Shorthouse, A.J. & Millar, J.L. A comparison of the response of human lung carcinoma xenografts to vindesine and vincristine. Br. J. Cancer. 45, 466–468 (1982).

    Article  CAS  Google Scholar 

  50. Segal, G.M., et al. Repression of Fanconi anemia gene (FACC) expression inhibits growth of hematopoietic progenitor Cells. J. Clin. Invest. 94, 846–852 (1994).

    Article  CAS  Google Scholar 

  51. Hernandez, A., et al. Detection of the hybrid BCR/ABL messenger RNA in single CFU-GM colonies using the polymerase chain reaction. Exp. Hematol. 18, 1142–1144 (1990).

    CAS  PubMed  Google Scholar 

  52. Dunn, O.J. Multiple comparisons using rank sums. Technometrics 6, 241–252 (1964).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Druker, B., Tamura, S., Buchdunger, E. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells. Nat Med 2, 561–566 (1996). https://doi.org/10.1038/nm0596-561

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0596-561

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing